

Ref. No: 1297
Date: 23/10/24
Subject: Chronic lymphocytic leukaemia (CLL)

REQUEST

Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

1. How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?

Answer:

2. How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

Answer:

3. Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024
 - FCR (fludarabine + cyclophosphamide + rituximab)
 - FR (fludarabine + rituximab)
 - BR (bendamustine + rituximab)
 - Bendamustine monotherapy
 - RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
 - Obinutuzumab ± chlorambucil
 - Rituximab + chlorambucil
 - Ofatumumab
 - Other – please specify

Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window

Answer:

Treatment option	Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024
FCR	
FR	
BR	
Bendamustine monotherapy	
R-CHOP	
Obinutuzumab ± chlorambucil	
Rituximab + chlorambucil	
Chlorambucil monotherapy	
Rituximab monotherapy	
Ofatumumab	
Other – please specify	

RESPONSE